Stemcells Inc: (NASD: STEM)
$1.88
0.01 (0.54%)
Volume 240,459
May 23 04:00 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 1.82 - 1.88 |
| 52wk Low - High | 0.59 - 2.67 |
| Previous Close | 1.87 |
| Avg. Volume | 427,430 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 72.70 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.42 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
95 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.38 |
| Expected Earnings Growth | NA |
Company Description
Stemcells, Inc. is engaged in research aimed at the development of therapies that would use stem and progenitor cells derived from fetal or adult sources to treat, and possibly cure, human diseases and injuries such as Parkinson's disease, hepatitis, diabetes, and spinal cord injuries.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 13.75 | |
|
| GENTIUM SPA-ADR | GENT | 8.79 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACADIA PHARMA | ACAD | 13.42 | |
|
| ACHILLION PHARM | ACHN | 7.74 | |
|
| ADDEX THERA LTD | ADDXF | 6.62 | |
|
| AFFYMAX INC | AFFY | 1.40 | |
|
| ALEXION PHARMA | ALXN | 100.57 | |
|
| ALKERMES INC | ALKS | 31.75 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.38 |
| Sales | 1 |
| Net Income | -25 |
| Price/Earnings | NA |
| Price/Book | 7.13 |
| Price/Cash Flow | NA |
| Price/Sales | 72.12 |
News
Cloning: A Stem Cell Revolution? - TheMotleyFool
May 19, 2013
4 Biotech Stocks Under $5 to Watch - TheStreet.com
Mar 15, 2013
Geron Earnings: An Early Look - TheMotleyFool
Mar 9, 2013
Stem Cells Have a Long Way to Go - TheMotleyFool
Feb 13, 2013
StemCells Shares Surge Following News of Completion of First Patient Cohort for Spinal Cord Injury Trial - Benzinga
Feb 12, 2013
CAPScall of the Week: Neuralstem - TheMotleyFool
Jan 2, 2013
UPDATE: Ascendiant Capital Markets Reiterates Buy Rating, Lowers PT on StemCells - Benzinga
Nov 12, 2012
StemCells Partners With R Biomedical - Benzinga
Oct 30, 2012
Broker Recommendations
| Current ABR | NA |
| ABR (Last Week) | NA |
| # of recs in ABR | NA |
| Average Target Price | NA |
| Industry Rank by ABR | 95 out of 265 |
| Rank in Industry | NA |
